Compare InMode Ltd. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 1,093 Million (Small Cap)
12.00
NA
0.00%
-0.81
13.73%
1.60
Revenue and Profits:
Net Sales:
82 Million
(Quarterly Results - Mar 2026)
Net Profit:
12 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.43%
0%
-7.43%
6 Months
-3.39%
0%
-3.39%
1 Year
-1.9%
0%
-1.9%
2 Years
-23.72%
0%
-23.72%
3 Years
-60.07%
0%
-60.07%
4 Years
-42.67%
0%
-42.67%
5 Years
-63.77%
0%
-63.77%
InMode Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.44%
EBIT Growth (5y)
3.23%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.83
Sales to Capital Employed (avg)
0.59
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
83.15%
ROCE (avg)
3,019.95%
ROE (avg)
30.67%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.60
EV to EBIT
6.33
EV to EBITDA
6.28
EV to Capital Employed
4.13
EV to Sales
1.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
65.14%
ROE (Latest)
13.73%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 66 Schemes (18.59%)
Foreign Institutions
Held by 125 Foreign Institutions (15.83%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
82.00
77.90
5.26%
Operating Profit (PBDIT) excl Other Income
10.20
15.80
-35.44%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
11.60
18.20
-36.26%
Operating Profit Margin (Excl OI)
122.60%
200.60%
-7.80%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 5.26% vs -2.99% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -36.26% vs -23.21% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
370.50
394.80
-6.16%
Operating Profit (PBDIT) excl Other Income
86.10
113.30
-24.01%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
93.80
181.30
-48.26%
Operating Profit Margin (Excl OI)
230.50%
285.00%
-5.45%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -6.16% vs -19.76% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -48.26% vs -8.39% in Dec 2024
About InMode Ltd. 
InMode Ltd.
Pharmaceuticals & Biotechnology
Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company’s proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company’s products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.






